← All Stocks

IDEXX Laboratories, Inc.

IDXX · NMS
$519.26+1.14%
52W Low: $500.6152W High: $769.98
Current: $519.26  ·  7% of 52-week range
HealthcareDiagnostics & ResearchNMS
View live charts, options flow & technicals for IDEXX Laboratories, Inc. → Open Dashboard

IDEXX Laboratories, Inc. (IDXX) is a healthcare company in the diagnostics & research industry with $4.55B in trailing revenue trading at a 37.0× trailing P/E — analyst consensus: buy.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Key Statistics

Market Cap$40.91B
Revenue (TTM)$4.55B
EPS (TTM)$14.02
EPS (Fwd est.)$16.74
Employees11,000
Trailing P/E37.04
Forward P/E31.02
PEG Ratio2.81
Price / Sales8.98
Price / Book25.40
EV / EBITDA25.78
Beta (5Y)1.54

Analyst Consensus

Consensus
Buy
Analyst Price Target
+35.1% upside
Target: $701.33

Annual Revenue & Net Income

RevenueNet Income
'22
$3.37B
$680.00M
'23
$3.66B
$850.00M
'24
$3.90B
$890.00M
'25
$4.30B
$1.06B

Earnings History


QuarterActual EPSEstimateResult
Aug 2026
$4.27
$3.93Beat (+8.5%)
May 2026
$3.47
$3.41Beat (+1.7%)
Feb 2026
$3.08
$2.94Beat (+4.8%)
Nov 2025
$3.40
$3.15Beat (+8.1%)

Next Earnings Report

IDEXX Laboratories, Inc. is next expected to report earnings on 02 Nov 2026.

Profitability

62.4%
35.0%
25.0%
Gross
Margin
Operating
Margin
Net
Margin
Revenue Growth (YoY)9.7%
Return on Equity74.2%
Return on Assets27.1%

Balance Sheet

Cash & Equivalents$200.00M
Total Debt$1.10B
Net Position$900.00M (net debt)
Free Cash Flow (TTM)$910.00M
Debt / Equity67.97

Share Ownership

Institutions 96.7%
Insiders 0.2%
Public 3.1%

Related Stocks

LLYUNHJNJMRKABBVTMOPFEISRG

Frequently Asked Questions

What does IDEXX Laboratories, Inc. (IDXX) do?
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine…
What is IDXX's market cap?
IDEXX Laboratories, Inc. has a market capitalization of approximately $40.91B.
What is IDXX's P/E ratio?
IDEXX Laboratories, Inc. trades at a trailing P/E ratio of 37.0x and a forward P/E of 31.0x, which is above the broad market average of ~25x.
How much revenue does IDXX generate?
IDEXX Laboratories, Inc. generated $4.55B in trailing 12-month revenue.
What do analysts say about IDXX?
The analyst consensus rating for IDEXX Laboratories, Inc. is buy, with a mean price target of $701.33. That implies +35.1% upside from the current price.
When does IDXX report earnings?
IDEXX Laboratories, Inc. is next scheduled to report earnings on 02 Nov 2026.
Does IDXX pay a dividend?
IDEXX Laboratories, Inc. does not currently pay a regular dividend.

View live charts, options flow, gamma exposure, earnings history, and technical analysis for IDEXX Laboratories, Inc. on Apsis Markets.

Open Live Dashboard →